Biomarker use for dementia with lewy body diagnosis: Survey of US experts

Melissa J. Armstrong, David J. Irwin, James B. Leverenz, Noheli Gamez, Angela Taylor, James E. Galvin

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background:Dementia with Lewy body (DLB) diagnostic criteria define "indicative" and "supportive" biomarkers, but clinical practice patterns are unknown.Methods:An anonymous survey querying clinical use of diagnostic tests/biomarkers was sent to 38 center of excellence investigators. The survey included "indicative" biomarkers (dopamine transporter scan, myocardial scintigraphy, polysomnography), "supportive" biomarkers [magnetic resonance imaging (MRI)], positron emission tomography, or single-photon emission computed tomography perfusion/metabolism scans, quantitative electroencephalography), and other diagnostic tests (neuropsychological testing, cerebrospinal fluid analysis, genetics). Responses were analyzed descriptively.Results:Of the 22 respondents (58%), all reported the capability to perform neuropsychological testing, MRI, polysomnography, dopamine transporter scans, positron emission tomography/single-photon emission computed tomography scans, and cerebrospinal fluid analysis; 96% could order genetic testing. Neuropsychological testing and MRI were the most commonly ordered tests. Diagnostic testing beyond MRI and neuropsychological testing was most helpful in the context of "possible" DLB and mild cognitive impairment and to assist with differential diagnosis. Myocardial scintigraphy and electroencephalograpy use were rare.Conclusions and Relevance:Neuropsychological testing and MRI remain the most widely used diagnostic tests by DLB specialists. Other tests-particularly indicative biomarkers-are used only selectively. Research is needed to validate existing potential DLB biomarkers, develop new biomarkers, and investigate mechanisms to improve DLB diagnosis.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalAlzheimer disease and associated disorders
Volume35
Issue number1
DOIs
StatePublished - 2021

Keywords

  • Biomarkers
  • Dementia with Lewy bodies
  • Diagnosis
  • Diagnostic tests
  • Lewy body disease
  • Routine

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Biomarker use for dementia with lewy body diagnosis: Survey of US experts'. Together they form a unique fingerprint.

Cite this